Erratum for “Simultaneous Targeting of De Novo Pyrimidine Synthesis and ATR Enhances ATF4-Driven Apoptosis in TP53-Deficient Acute Lymphoblastic Leukemia”
-
October 5, 2026
Clinical Report: Erratum for Simultaneous Targeting of De Novo Pyrimidine Synthesis
Background
TP53 mutations are prevalent in various malignancies but are rare in acute leukemias, particularly in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). The mechanisms of cell death in TP53-deficient ALL are important to understand.
Data Highlights
No numerical data or trial results are presented in the erratum.
Key Findings
- The article originally misdefined ATR as Activating Transcription Factor 4.
- ATR is correctly defined as Ataxia Telangiectasia and Rad3-related protein.
- Dual blockade of ATR and de novo pyrimidine synthesis promotes ATF4-mediated cell death in TP53-deficient ALL.
- TP53 mutations are rare in primary BCP-ALL, occurring in less than 3% at diagnosis.
- TP53 mutations are more common in relapsed cases of BCP-ALL.
Clinical Implications
The correction of ATR's definition is important for accurate communication in clinical research.
Conclusion
The erratum clarifies a critical definition.
Related Resources & Content
- Grünewald et al., HemaSphere, 2026 -- Simultaneous Targeting of De Novo Pyrimidine Synthesis and ATR Enhances ATF4-Driven Apoptosis in TP53-Deficient Acute Lymphoblastic Leukemia
- American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults | Blood Advances | American Society of Hematology
- Blood Cancer Journal — Amendment: Dual Targeting of BCL-2 and MCL-1 Surmounts Resistance in TP53-Mutant Acute Myeloid Leukemia Associated with BAX Deficiency to Single BH3 Mimetics
- Blood Cancer Journal — Correction: Targets for Bispecific Antibodies in Acute Myeloid Leukemia
- ASCO Publications — Erratum
- American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults | Blood Advances | American Society of Hematology
- Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia | New England Journal of Medicine
- Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults - PubMed
Based on findings from:
Correction to “Combined inhibition of de novo pyrimidine synthesis and ATR promotes ATF4-mediated cell death in TP53-deficient ALL”
Hemasphere, 2026.
https://onlinelibrary.wiley.com/doi/10.1002/hem3.70502
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
